Clinical Trial Update: LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment [Phase 3]

View source ↗

Summary

Phase 3 trial update for afatinib (BIBW 2992) in HER2-positive metastatic breast cancer after one prior Herceptin treatment completes; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Breast Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2014-08-21